0001493152-26-021710
SEC filingGenelux's net loss widened 19% to $8.9M in Q1 2026, driven by increased Phase 3 trial costs, while a January equity raise extended cash runway.
Genelux's operating loss for Q1 2026 was $9.2 million, compared to $7.8 million in the prior year period, a 17% increase. This widening loss was primarily driven by higher research and development expenses associated with the Phase 3 On Prime registration trial for Olvi-Vec. The company's R&D costs increased as clinical trial activities intensified, including patient enrollment and manufacturing scale-up. General and administrative expenses also rose, reflecting the costs of operating as a public company and supporting expanded operations.
Net loss for Q1 2026 was $8.9 million, or $0.20 per diluted share, compared to a net loss of $7.5 million, or $0.21 per diluted share, in Q1 2025. While the net loss increased by 19%, the diluted loss per share improved due to a higher weighted-average share count resulting from the January 2026 equity offering. The improvement in EPS reflects the dilutive effect of additional shares outstanding, which partially offset the larger net loss on a per-share basis.